Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma

Chimeric antigen receptor (CAR) T-cell based immunotherapy has become a promising treatment mainly for hematological malignancies. Following the major success of CD19-targeted CAR, new potential targets for other malignancies are required. As such, B-cell maturation antigen (BCMA) is an attractive t...

Descripción completa

Detalles Bibliográficos
Autores principales: Harush, Ortal, Asherie, Nathalie, Kfir-Erenfeld, Shlomit, Adler, Galit, Barliya, Tilda, Assayag, Miri, Gatt, Moshe E., Stepensky, Polina, Cohen, Cyrille J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521250/
https://www.ncbi.nlm.nih.gov/pubmed/35354252
http://dx.doi.org/10.3324/haematol.2021.280169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521250/
https://www.ncbi.nlm.nih.gov/pubmed/35354252
http://dx.doi.org/10.3324/haematol.2021.280169

Ejemplares similares